Hormonal
Combining gut hormone analog medications (e.g., GLP-1/GIP agonists) with naltrexone-bupropion extended-release (NB-ER) provides a mechanistic rationale for improved weight loss in patients who fail to achieve goals with monotherapy, by targeting distinct satiety and reward pathways.
If you are taking a GLP-1 medication (like semaglutide or tirzepatide) and hitting a plateau or struggling with food cravings despite following the dose, ask your doctor about adding NB-ER (naltrexone-bupropion). This combination targets both physical fullness and the brain's reward system, which may help you lose more weight than the single medication alone.
The distinct yet complementary effects of gut hormone analog medications and NB-ER on gut-brain pathways regulating satiety, hunger, and reward provide a mechanistic rationale for their combination in obesity treatment.
Why this rating
Based on a review of multiple RCTs and post-hoc analyses, though direct head-to-head combination RCTs are noted as needing future study.
Source
Targeting Multiple Gut‐Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy
Alexander D. Miras et al. · Obesity Science & Practice · 2026
DOI 10.1002/osp4.70141
More from this paper
- Gut hormone analog medications (liraglutide, semaglutide, tirzepatide) reduce energy intake and alter food preferences primarily through delayed gastric emptying and hypothalamic/brainstem satiety signaling, rather than direct effects on reward centers.Good
- NB-ER (naltrexone-bupropion extended-release) reduces food cravings and improves control over eating by acting on central hypothalamic and mesolimbic dopaminergic systems, distinct from the peripheral effects of gut hormone analogs.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →